Ludotadipep is under clinical development by FutureChem and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ludotadipep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ludotadipep overview

Ludotadipep is under development for the treatment of metastatic castration-resistant prostate cancer. It is administered through intravenous route. It is a Lu-177 radiolabeled compound. It acts by targeting PSMA.

FutureChem overview

FutureChem is engaged in the manufacture of medicaments. The company offers radiopharmaceuticals for the diagnosis of cancer, lung cancer, Parkinson’s disease and Alzheimer’s disease. The company is also involved in chemical business which produces and develops PET and SPECT precursors, linkers, fluorescence probe, ionic liquid, amino acids and reagent for peptide. In addition, it also offers automation modules such as sCUBE RXN, sCUBE P&F, sCUBE A sCUBE M, and disposable goods includes Cassette, Reagent Kit and Radio-Cap. FutureChem is headquartered in Seongdong-gu, Seoul, South Korea.

For a complete picture of Ludotadipep’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.